July 22, 2025 5:04pm

Volatility, macroeconomic and geopolitical uncertainty, need for Fed accountability, new tariff developments, good earnings followed by declines in Nasdaq

News: Sarepta Therapeutics (SRPT +$0.29 or +2.21% to $13.62) bows to FDA pressure, pulls Duchenne therapy from market after initially rebuffing an FDA request to stop shipping its gene therapy for Duchenne muscular dystrophy over safety concerns

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Tuesday’s RegMed Investors’ (RMi) pre-open: trading places … https://www.regmedinvestors.com/articles/14007

Monday night’s RegMed Investors (RMi) Closing Bell: flipping share pricing burgers on high … https://www.regmedinvestors.com/articles/14006

RegMed Investors (RMi) Research Note: Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The Dow closed UP +179.37 points or +0.40%, the S&P closed UP +4.02 points or +0.06% while the Nasdaq closed DOWN – 81.49 points or -0.39%

  • Theme of the session, weighed the latest earnings reports and new trade developments
  • The day after both indexes hit fresh records and bogged down by a decline in chip stocks

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • No words from Fed meeting

Tuesday’s advance/decline line opened negative with 12 incliners, 18 decliners and 5 flats ending with a positive close of 19 incliners, 10 decliners and 6 flats      

Metrics:  Tuesday, the IBB was up +3.71%, the XBI was up +0.86% while the VIX was down -0.15 points or -0.90% at 16.50

 

Q3 – 7/25 – 1 market holiday, 11 positive and 4 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Tuesday Closing UP (10 of 19) 

  • Alnylam Pharmaceuticals (ALNY +$4.78),
  • Vericel (VCEL +$2.52 after Monday’s +$0.12 after Friday’s -$0.92),
  • Moderna (MRNA +$1.76 after Monday’s -$0.29 after Friday’s -$0.94)
  • AxoGen (AXGN +$0.93 after Monday’s +$0.33 after Friday’s -$0.35),
  • Intellia Therapeutics (NTLA +$0.86 after Monday’s +$0.57 after Friday’s +$0.23),
  • BioLife Solutions (BLFS +$0.65 after Monday’s -$0.07 after Friday’s -$0.59),
  • CRISPR Therapeutics (CRSP +$0.60 after Monday’s +$0.20 after Friday’s +$10.04),
  • Beam Therapeutics (BEAM +$0.51 after Monday’s +$0.28 after Friday’s +$0.30),
  • Mesoblast (MESO +$0.43 after Monday’s -$0.97 after Friday’s +$3.28),
  • Ionis Pharmaceuticals (IONS +$0.40 after Monday’s -$0.21 after Friday’s -$0.41),

Flat (6)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Cellectis SA (CLLS)
  • Compass Therapeutics (CMPX)
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Tuesday’s Closing DOWN (10 of 10): 

  • Lenz Therapeutics (LENZ -$0.60 after Monday’s -$0.15 after Friday’s -$0.84),
  • Precigen (PGEN -$0.31),
  • uniQure NV (QURE -$0.25 after Monday’s -$0.49),
  • Sage Therapeutics (SAGE -$0.22 after Monday’s -$0.14),
  • Solid Biosciences (SLDB -$0.14),
  • Brainstorm Cell Therapeutics (BCLI -$0.065 after Monday’s -$0.0701 after Friday’s $0.00)
  • Adverum Biotechnologies (ADVM -$0.04),
  • Prime Medicine (PRME -$0.04 after Monday’s +$0.44 after Friday’s +$0.23),
  • Sangamo Therapeutics (SGMO -$0.0148),
  • Voyager Therapeutics (VYGR -$0.01 after Monday’s -$0.07 after Friday’s +$0.02),

 

The BOTTOM LINE: “Bada-bing” … Is an exclamation suggesting that something is going to happen, easily and predictably

U.S. stocks drifted to another record following some mixed profit reports …

Investors flocked to the health-care sector in particular, which outperformed with a rise of nearly 2% on the day. That was bolstered by the advance of IQVIA which soared 18% on the heels of an earnings and revenue beat, leading the S&P 500 – as well as other names like Amgen and Merck. Small-caps also outperformed, as the Russell 2000 jumped about 1%. <CNBC>

The Russell 2000 index of smaller companies rose 17.63 points, or 0.8%, to 2,248.76.

 

For the week till Tuesday:

  • The S&P 500 is up 12.83 points, or 0.2%.
  • The Dow is up 160.25 points, or 0.4%.
  • The Nasdaq is down 2.97 points, or less than 0.1%.
  • The Russell 2000 is up 8.75 points, or 0.4%.

 

The cell and gene therapy sector closed Tuesday ((7/22) and Monday positive

  • After slipping last Friday (7/18) following a positive close on last Thursday and Wednesday having slid on Tuesday after Monday’s positive close
  • And popping on the previous Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday 
  • After the previous, previous week’s pop on multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

 

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

 

As I also wrote, the “June Swoon” is over … however, July is better than any other month - so far. 

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

July evolves: understand the “flow” …

  • 7/22 – Tuesday closed positive with 19 positive, 10 negative and 6 flats
  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

Last week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

The previous week:

  • 7/11 - Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and moderna (MRNA)
  • Monday: CRISPR Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY) and Intellia Therapeutics (NTLA)
  • Friday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Solid Biosciences (SLDB)

The worst three (3) in the session: 

  • Tuesday: Lenz Pharmaceuticals (LENZ), Precigen (PGEN) and uniQure NV (QURE)
  • Monday: Mesoblast (MESO), Vericel (VCEL) and uniQure NV (QURE)
  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Ultragenyx Pharmaceuticals RARE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.